US equities |
TSLA $391.62 ▲+5.21% MU $903.70 ▲+2.98% META $630.56 ▼-1.88% NVDA $216.00 ▲+2.39% AAPL $343.91 ▼-1.10% SPCX $146.90 ▼-0.40% MSFT $532.60 ▲+1.54% AMD $531.28 ▲+2.80%
FinancialContent

TransMedics Group, Inc. - Common Stock (NQ:TMDX)

70.63 -0.11 (-0.16%)
Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TransMedics Group, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
News headline image
TransMedics Director David Weill Purchases $109,000 of Stock -- Should Investors Buy Too? ↗
Weill's acquisition increased his direct holdings to 16,392 shares, valued at $1.4 million at recent market prices, amid a 30% decline in the stock over the past year. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
2 Stocks Down 28% and 34% to Buy and Hold ↗
These companies' sell-offs may have gone too far. 
Via The Motley Fool
News headline image
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
From Kahn Swick & Foti, LLC
Via Business Wire
TransMedics Group (NASDAQ:TMDX) Falls as Q2 Earnings Miss Offsets Inline Revenue ↗
Via Chartmill
Topics Earnings
TransMedics Group (NASDAQ:TMDX): An Affordable Growth Stock With Strong Earnings Momentum ↗
Via Chartmill
TransMedics Group (NASDAQ:TMDX) Screens as an Affordable Growth Stock with Strong Momentum ↗
Via Chartmill
News headline image
TransMedics Targets $2B Opportunity With Kidney Push, European Expansion ↗
TransMedics Group (NASDAQ:TMDX) outlined its growth strategy at Canaccord Genuity’s 46th Annual Global Growth Conference, highlighting investments in kidney transplantation, European expansion,... 
Via MarketBeat
News headline image
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
TransMedics (TMDX) Q2 2026 Earnings Call Transcript ↗
Revenue hit $189.9 million with 21% growth as organ transplant volumes surge. 
Via The Motley Fool
Topics Earnings
TransMedics Group Inc (NASDAQ:TMDX): An Affordable Growth Play With Strong Fundamentals ↗
Via Chartmill
TransMedics Group Inc (NASDAQ:TMDX) – A Prime Example of Affordable Growth in Medical Technology ↗
Via Chartmill
TransMedics Group Inc (NASDAQ:TMDX) Plunges 27% After Major Q1 Earnings Miss ↗
Via Chartmill
News headline image
Why TransMedics Stock Is Sinking Today ↗
TransMedics stock slipped on mixed results, but its future remains bright. 
Via The Motley Fool
News headline image
TransMedics Group Q2 Earnings Call Highlights ↗
TransMedics Group (NASDAQ:TMDX) reported record second-quarter revenue as growth in liver procedures, clinical services and transplant logistics offset increased spending on product development,... 
Via MarketBeat
Topics Earnings
News headline image
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX
From Rosen Law Firm
Via Business Wire
News headline image
Where Will TransMedics Group Stock Be in 10 Years? ↗
Shares are down nearly 45%, but this healthcare innovator may be quietly building the logistics backbone of organ transplantation for decades to come. 
Via The Motley Fool
TransMedics Group Inc. (NASDAQ:TMDX) Combines Strong Earnings Momentum with Bullish Technical Setup ↗
Via Chartmill
News headline image
3 Growth Stocks to Buy on the Dip ↗
Don't wait until they recover. 
Via The Motley Fool
News headline image
What a $722,000 TransMedics Insider Sale Might Mean After a 45% Stock Drop ↗
Specializing in organ preservation technology, this medical device innovator reported a notable insider sale amid ongoing sector challenges. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Growth Stocks Worth $5,000 of Your Money -- Even in This Market ↗
Credo, Cellebrite, and TransMedics are building dominant positions in huge markets with years of expansion still ahead. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
This Healthcare Infrastructure Stock Is Risky, But the Upside Looks Huge ↗
The stock plunged, but its transplant platform may still be building a powerful moat. Is this a rare opportunity, or a margin trap? 
Via The Motley Fool
News headline image
My Top 3 Stocks to Buy in May ↗
Forget "sell in May and go away." These stocks are good picks to buy and hold. 
Via The Motley Fool
Topics Earnings
News headline image
TransMedics (TMDX) Q1 2026 Earnings Transcript ↗
TransMedics (TMDX) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Economy
These stocks are moving in today's pre-market session ↗
Via Chartmill
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Via Chartmill
News headline image
2 Healthcare Stocks That Could Outperform the Market Over the Next Decade ↗
Both have helped transform their respective industries. 
Via The Motley Fool
News headline image
Another Day, Another Massive AI Infrastructure Deal ↗
The Hidden Gems team discusses the latest AI infrastructure deal between Meta Platforms and neocloud company Nebius, then delves into consumer spending via Dollar Tree's 2025 results. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
TransMedics Stock Is Up 104% Over the Last Year: Is It Too Late to Buy for 2026? ↗
TransMedics continues to reinvent the organ transplant industry, but the market insists the stock is "overvalued" now. 
Via The Motley Fool
News headline image
4 Top Stocks Long-Term Investors Should Buy in March ↗
Four dominant, cash-generating compounders just went on sale. The fundamentals say the long-term story is only getting stronger. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Got $5,000? TransMedics Could Be a High‑Tech Organ Transplant Moonshot ↗
The mid-cap healthcare specialist is definitely worth a second look. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >